BE1001075A3 - Nouvelle composition ophtalmologique. - Google Patents
Nouvelle composition ophtalmologique. Download PDFInfo
- Publication number
- BE1001075A3 BE1001075A3 BE8800497A BE8800497A BE1001075A3 BE 1001075 A3 BE1001075 A3 BE 1001075A3 BE 8800497 A BE8800497 A BE 8800497A BE 8800497 A BE8800497 A BE 8800497A BE 1001075 A3 BE1001075 A3 BE 1001075A3
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- acid
- corneal
- cellulose
- days
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 19
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000725 suspension Substances 0.000 claims abstract description 7
- 229920013820 alkyl cellulose Polymers 0.000 claims abstract description 5
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical group CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 14
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 17
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- 210000004087 cornea Anatomy 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 206010011033 Corneal oedema Diseases 0.000 description 8
- 201000004778 corneal edema Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 208000006069 Corneal Opacity Diseases 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079920 digestives acid preparations Drugs 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000018931 inflamed eyes Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878710780A GB8710780D0 (en) | 1987-05-07 | 1987-05-07 | Opthalmological application of eicosapentaenoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1001075A3 true BE1001075A3 (fr) | 1989-06-27 |
Family
ID=10616936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE8800497A BE1001075A3 (fr) | 1987-05-07 | 1988-05-03 | Nouvelle composition ophtalmologique. |
Country Status (19)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2657018A1 (fr) * | 1990-01-12 | 1991-07-19 | Merck Sharp & Dohme | Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation. |
| ES2059880T3 (es) * | 1990-05-23 | 1994-11-16 | Nestle Sa | Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias. |
| GB9012651D0 (en) * | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
| US5444452A (en) * | 1992-07-13 | 1995-08-22 | Matsushita Electric Works, Ltd. | Dual frequency antenna |
| DE4330664A1 (de) * | 1993-09-10 | 1995-03-16 | Beiersdorf Ag | Verwendungen von Pflanzenölen |
| FR2722410B1 (fr) * | 1994-07-15 | 1996-10-04 | Grinda Jean Robert | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique |
| DE19503993A1 (de) * | 1995-02-08 | 1996-08-14 | Johann Friedrich Dr Med Desaga | Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen |
| RU2135129C1 (ru) * | 1998-11-18 | 1999-08-27 | Ларионов Евгений Викторович | Глазные капли "корнеалон-плюс" |
| EP1338279A1 (en) * | 2000-11-08 | 2003-08-27 | Santen Pharmaceutical Co., Ltd. | Remedies for keratoconjunctival diseases containing farnesyl acetate as the active ingredient |
| EP1781278B2 (en) * | 2004-07-01 | 2019-10-16 | Schepens Eye Research | Compositions and methods for treating eye disorders and conditions |
| US20070265341A1 (en) * | 2004-07-01 | 2007-11-15 | The Schepens Eye Research Institute Inc. | Compositions and methods for treating eye disorders and conditions |
| CA2611909C (en) * | 2005-07-01 | 2014-01-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition for treatment of corneal disease |
| CN101222939B (zh) * | 2005-07-13 | 2010-11-24 | 参天制药株式会社 | 眼科用防腐组合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2426461A1 (fr) * | 1978-05-26 | 1979-12-21 | Wellcome Found | Acides gras, derives de ceux-ci et medicaments qui en contiennent |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT269345B (de) * | 1965-07-20 | 1969-03-10 | Merck & Co Inc | Verfahren zur Herstellung einer sterilen, von festen Teilchen freien Zubereitung für die Augenheilkunde |
| US3549747A (en) * | 1968-02-20 | 1970-12-22 | Flow Pharma Inc | Contact lens wetting solution and method of using same |
| GB1340517A (en) * | 1969-12-01 | 1973-12-12 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
| GB2020180B (en) * | 1978-05-08 | 1982-08-25 | Nelson Res & Dev | Ophthalmic compositions containingcolchicine or vinblastinr |
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| FR2548021B1 (fr) * | 1983-06-29 | 1986-02-28 | Dick P R | Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels |
| US4616012A (en) * | 1983-11-25 | 1986-10-07 | Schering Corporation | Carboxyalkyl dipeptides as antiglaucoma agents |
| GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| JPS6344843A (ja) * | 1986-08-13 | 1988-02-25 | Kao Corp | 油中水中油型乳化油脂組成物 |
-
1987
- 1987-05-07 GB GB878710780A patent/GB8710780D0/en active Pending
-
1988
- 1988-04-22 NZ NZ224363A patent/NZ224363A/xx unknown
- 1988-04-26 ZA ZA882963A patent/ZA882963B/xx unknown
- 1988-04-28 IN IN373/DEL/88A patent/IN169811B/en unknown
- 1988-04-29 MY MYPI88000451A patent/MY103079A/en unknown
- 1988-04-29 IT IT8820388A patent/IT1217446B/it active
- 1988-04-29 CH CH1620/88A patent/CH675359A5/fr not_active IP Right Cessation
- 1988-04-29 NL NL8801125A patent/NL8801125A/nl not_active Application Discontinuation
- 1988-04-29 FR FR888805735A patent/FR2614790B1/fr not_active Expired - Lifetime
- 1988-05-03 GB GB8810422A patent/GB2204239B/en not_active Expired - Lifetime
- 1988-05-03 BE BE8800497A patent/BE1001075A3/fr not_active IP Right Cessation
- 1988-05-05 OA OA59347A patent/OA08843A/xx unknown
- 1988-05-05 SE SE8801710A patent/SE8801710L/xx not_active Application Discontinuation
- 1988-05-06 DK DK250088A patent/DK250088A/da unknown
- 1988-05-06 US US07/190,761 patent/US4897421A/en not_active Expired - Fee Related
- 1988-05-06 LU LU87210A patent/LU87210A1/fr unknown
- 1988-05-06 DE DE3815581A patent/DE3815581A1/de not_active Withdrawn
- 1988-05-06 AU AU15678/88A patent/AU1567888A/en not_active Abandoned
- 1988-05-06 JP JP63109221A patent/JPS63297323A/ja active Pending
- 1988-05-06 KR KR1019880005253A patent/KR880013557A/ko not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2426461A1 (fr) * | 1978-05-26 | 1979-12-21 | Wellcome Found | Acides gras, derives de ceux-ci et medicaments qui en contiennent |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 103, no. 15, 14 octobre 1985, page 160, résumé no. 117037d, Columbus, Ohio, US; P.S. KULKARNI et al.: "Prostaglandins E3 and D3 lower intraocular pressure", & INEST. OPHTHALMOL. VISUAL SCI. 1985, 26(8), 1178-82 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US4897421A (en) | 1990-01-30 |
| FR2614790B1 (fr) | 1991-05-31 |
| AU1567888A (en) | 1988-11-10 |
| GB8710780D0 (en) | 1987-06-10 |
| MY103079A (en) | 1993-04-30 |
| FR2614790A1 (fr) | 1988-11-10 |
| DK250088A (da) | 1988-11-08 |
| LU87210A1 (fr) | 1988-12-13 |
| DE3815581A1 (de) | 1988-11-17 |
| NL8801125A (nl) | 1988-12-01 |
| IT8820388A0 (it) | 1988-04-29 |
| SE8801710D0 (sv) | 1988-05-05 |
| GB2204239B (en) | 1990-11-28 |
| IN169811B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-12-28 |
| GB2204239A (en) | 1988-11-09 |
| SE8801710L (sv) | 1988-11-08 |
| CH675359A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-09-28 |
| OA08843A (fr) | 1989-03-31 |
| IT1217446B (it) | 1990-03-22 |
| JPS63297323A (ja) | 1988-12-05 |
| DK250088D0 (da) | 1988-05-06 |
| KR880013557A (ko) | 1988-12-21 |
| ZA882963B (en) | 1988-10-28 |
| GB8810422D0 (en) | 1988-06-08 |
| NZ224363A (en) | 1990-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1001075A3 (fr) | Nouvelle composition ophtalmologique. | |
| AU616713B2 (en) | Use of fatty acids against cyclosporin side effects | |
| TW201410248A (zh) | 處理週邊血管疾患之方法及組成物 | |
| BE1003578A4 (fr) | Nouvelles compositions ophtalmiques a base d'une cyclosporine. | |
| NZ248422A (en) | Use of(dihomo-)gamma-linolenic acid (dgla,gla) or linoleic acid(la) to increase gut calcium absorption in humans | |
| CN101720223B (zh) | 血管活性物质与雌激素类的组合及其在治疗女性性功能障碍中的应用 | |
| Armin et al. | An explanation for the heightened vascular reactivity of the denervated rabbit's ear | |
| FR2491475A1 (fr) | Procede de preparation de sulfate de chondroitine et composition pharmaceutique contenant ce dernier | |
| KR20190050800A (ko) | 트리테르페노이드를 포함하는 조성물 및 시신경병증을 치료하기 위한 이의 용도 | |
| EP1656131B1 (fr) | Utilisation de la betaine pour le traitement de la claudication intermittente | |
| TWI284529B (en) | A composition for lowering triglyceride | |
| JPH08198766A (ja) | 新規組成物及び当該組成物を用いた組成物並びにそれらの製造方法、それらの分子同定方法、それらを用いた、人体および動物に対して治療効果を有する炎症剤、鎮痛剤、止痒剤、解熱剤 | |
| JPH0717515B2 (ja) | 良性前立腺肥大治療用組成物 | |
| FR2487195A1 (fr) | Procede et composition permettant d'abaisser le taux de cholesterol contenu dans le sang | |
| JP2664111B2 (ja) | 動物及び人における高コレステロール症及び高リポプロテインｉｉ型症及び性的挙動の刺激の処置に使用する高級一級脂肪族アルコールの混合物を含む医薬製剤 | |
| Takasugi et al. | Prevention of acute experimental pancreatitis in rats and dogs by intraduodenal infusion of a synthetic trypsin inhibitor | |
| JPH09241159A (ja) | Ｈｓｐ６０ファミリーに属するタンパク質のアトラクチレノライドｉｉｉ 含有合成抑制剤 | |
| Shafiroff et al. | Intravenous infusions into human subjects of fractionated coconut oil emulsions | |
| FR2459658A1 (fr) | Procede de preparation d'une composition pharmaceutique a base de methoxsalen administrable par voie orale | |
| JPS58140072A (ja) | １，３−ジオキソ−１Ｈ−ベンズ（ｄｅ）イソキノリン−２（３Ｈ）酪酸及びその医薬として許容される塩、並びにこれらを含有する医薬 | |
| Verbey et al. | Modulation of immunogenic keratitis in rabbits by topical administration of poly-unsaturated fatty acids | |
| JP3917825B2 (ja) | 血管新生抑制剤 | |
| JP4473968B2 (ja) | 血球流動性改善剤 | |
| JPH1036267A (ja) | Ｈｓｐ２７ファミリーに属するタンパク質のエボジアミン誘導体含有合成抑制剤 | |
| Schwartz et al. | Renal arachidonic acid metabolism and cellular changes in the rabbit renal vein constricted kidney: inflammation as a common process in renal injury models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: SOC. DE CONSEILS DE RECHERCHES ET D APPLICATIONS S Effective date: 19910531 |